ClinicalTrials.gg
TerminatedNCT01928615LISAHUpdated Sep 29, 2014Results posted

A Study of Subcutaneously Administered Herceptin (Trastuzumab) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer

A Phase 2 interventional study of Trastuzumab - intravenous solution and Trastuzumab - subcutaneous solution in Breast Cancer, sponsored by Hoffmann-La Roche. Terminated at 2 sites in Austria. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-09-29.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Why this study was terminated
Problems with drug supply

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
2
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 374 studies testing trastuzumab in Breast Neoplasms — 57 open to participants now, 86 under way, 5 of them phase 3. Trastuzumab · Breast Neoplasms.

Enrollment
348th of 366
2 · median 61
Started
2013
with 25 others
Phase 2
239 of 374
44 open now
Registered
204th of 374
by date
Lead sponsor
31 of 374
Hoffmann-La Roche

Among the 374 studies testing trastuzumab in Breast Neoplasms, this one is the 348th largest by enrollment of the 366 interventional ones that give a count, is one of 26 that started in 2013, is one of 239 in phase 2, and was the 204th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

57 of the 374 studies testing trastuzumab in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

52 more — sign in →

By country, each count listing its studies:

All 57 open studies →

About trastuzumab

Trastuzumab: first FDA approval 1998 (HERCEPTIN), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 374 studies testing trastuzumab in Breast Neoplasms, or all of them as a file.
02

Study summary

This open-label, randomized crossover study evaluated the quality of life, efficacy, and safety of subcutaneous Herceptin (trastuzumab) injected either into the thigh or the upper arm of participants with early HER2-positive breast cancer.

Read the detailed description

In the run-in phase, participants received trastuzumab intravenously every 3 weeks for 18 weeks (Cycles 1-6). They first received trastuzumab 8 mg/kg once (Cycle 1) followed by trastuzumab 6 mg/kg 5 times for 15 weeks (Cycles 2-6). Participants could also receive a maximum of 6 cycles of standard chemotherapy for early breast cancer (neo-adjuvant or adjuvant) in the run-in phase.

Following the run-in phase, participants were randomized to receive trastuzumab 600 mg subcutaneously every 3 weeks in the thigh and upper arm in a cross-over design for a total of 24 weeks (Cycles 7-14). They received trastuzumab either in the thigh first for 4 cycles (Cycles 7-10) followed by trastuzumab in the upper arm for 4 cycles (Cycles 11-14) or the upper arm first (Cycles 7-10) followed by the thigh (Cycles 11-14). For Cycles 15-18, participants could choose the injection site for trastuzumab 600 mg subcutaneously every 3 weeks.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female and male patients ≥ years of age.
  • -positive early breast cancer.
  • (ECOG) performance status 0-1.
  • Hormonal therapy will be allowed as per institutional guidelines.
  • Patients must be Herceptin (trastuzumab) naïve.
  • (LVEF) of ≥ 55%.
  • confirmed non- primary invasive adenocarcinoma of the breast.
  • No evidence of residual, locally recurrent, or metastatic disease after completion of surgery and chemotherapy, or during concurrent chemotherapy ( or adjuvant).
  • Use of concurrent curative radiotherapy will be permitted.

Exclusion criteria

Exclusion Criteria:

  • History of other which could affect compliance with the protocol or interpretation of results. Patients with curatively treated carcinoma in situ of the cervix or basal cell carcinoma, and patients with other curatively treated malignancies who have been disease-free for at least 5 years, are eligible.
  • Patients with severe dyspnea at rest or requiring supplementary oxygen therapy.
  • Patients with other concurrent serious diseases that may interfere with planned treatment, including severe pulmonary conditions/illness.
  • Serious cardiac illness or medical conditions that would preclude the use of Herceptin, specifically, a history of documented congestive heart failure (CHF), high-risk uncontrolled arrhythmias, angina pectoris requiring medication, valvular disease, evidence of transmural infarction on (ECG), or diagnosed poorly controlled hypertension.
  • Pregnant or lactating women.
  • Women of and male patients with partners of childbearing potential who are unable or unwilling to use adequate measures during study treatment.
  • Concurrent enrollment in another clinical trial using an anti-cancer treatment, including hormonal therapy, bisphosphonate therapy, and immunotherapy, within 28 days prior to the first dose of study treatment.
  • Known to trastuzumab, murine proteins, to any of the of Herceptin including hyaluronidase, or a history of severe allergic or immunological reactions, eg, difficult to control asthma.
  • Inadequate bone marrow, hepatic, or renal function.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
2 participants (actual)

Study arms

  • Experimental
    Trastuzumab - Thigh first, then upper arm

    In the run-in phase, participants received trastuzumab intravenously every 3 weeks for 18 weeks (Cycles 1-6). They first received trastuzumab 8 mg/kg once (Cycle 1) followed by trastuzumab 6 mg/kg 5 times for 15 weeks (Cycles 2-6). Participants could also receive a maximum of 6 cycles of standard chemotherapy for early breast cancer (neo-adjuvant or adjuvant) in the run-in phase. Following the run-in phase, participants received trastuzumab 600 mg subcutaneously (SC) every 3 weeks into the thigh for 12 weeks (Cycles 7-10) followed by trastuzumab 600 mg SC every 3 weeks into the upper arm for 12 weeks (Cycles 11-14). In Cycles 15-18, participants received trastuzumab 600 mg SC every 3 weeks into either the thigh or the upper arm (participant's choice) for 12 weeks (Cycles 15-18).

    Drug: Trastuzumab - intravenous solution · Drug: Trastuzumab - subcutaneous solution · Drug: Chemotherapy

  • Experimental
    Trastuzumab - Upper arm first, then thigh

    In the run-in phase, participants received trastuzumab intravenously every 3 weeks for 18 weeks (Cycles 1-6). They first received trastuzumab 8 mg/kg once (Cycle 1) followed by trastuzumab 6 mg/kg 5 times for 15 weeks (Cycles 2-6). Participants could also receive a maximum of 6 cycles of standard chemotherapy for early breast cancer (neo-adjuvant or adjuvant) in the run-in phase. Following the run-in phase, participants received trastuzumab 600 mg subcutaneously (SC) every 3 weeks into the upper arm for 12 weeks (Cycles 7-10) followed by trastuzumab 600 mg SC every 3 weeks into the thigh for 12 weeks (Cycles 11-14). In Cycles 15-18, participants received trastuzumab 600 mg SC every 3 weeks into either the thigh or the upper arm (participant's choice) for 12 weeks (Cycles 15-18).

    Drug: Trastuzumab - intravenous solution · Drug: Trastuzumab - subcutaneous solution · Drug: Chemotherapy

Interventions

  • Trastuzumab was supplied as a powder to be reconstituted as a solution for intravenous infusion.

    Also known as: Herceptin, Ro 45-2317

  • Trastuzumab was supplied as a solution for subcutaneous injection.

    Also known as: Herceptin, Ro 45-2317

  • DrugChemotherapy

    Standard chemotherapy for early breast cancer.

06

What researchers measure

Primary outcomes

  1. Quality of Life Score

    Participants rated their quality of life on a visual analog scale (VAS) at the end of each cycle for Cycles 7-14. The left-end of the VAS represented the lowest-rated quality of life and the right-end of the VAS represented the highest-rated quality of life. Both the mean ratings for injections into the thigh and the upper arm and the minimum ratings for during injections into the thigh and the upper arm are reported. Quality of life scores ranged from 1 to 100 with a higher score indicating a better rated quality of life.

    Time frame: Cycles 7-14 (Weeks 19-42, 24 weeks total)

Secondary outcomes

  1. Overall Survival

    Overall survival was defined as the time in months from Baseline to death from any cause.

    Time frame: Baseline to the end of the study (up to 54 weeks)

  2. Disease-free Survival

    Disease-free survival was defined as the time in months from Baseline to disease recurrence or death, whichever occurred first.

    Time frame: Baseline to the end of the study (up to 54 weeks)

  3. Health Care Provider's Satisfaction With the Injection Site

    The health care provider for each participant was asked to rate their satisfaction with the 2 injection sites, thigh and upper arm, on a scale of 1 to 10, where 10 represents greater satisfaction. Ratings were made at the end of Cycles 10 and 14.

    Time frame: End of Cycles 10 and 14 (Weeks 30 and 42)

  4. Participant's Satisfaction With the Injection Site

    Each participant was asked to rate their satisfaction with the 2 injection sites, thigh and upper arm, on a scale of 1 to 10, where 10 represents greater satisfaction. Ratings were made at the end of Cycles 10 and 14.

    Time frame: End of Cycles 10 and 14 (Weeks 30 and 42)

  5. Percentage of Participants Preferring Each Injection Site

    Participants were asked which of the 2 injection sites was their preferred site at the end of Cycle 14.

    Time frame: End of Cycle 14 (Week 42)

07

Results

Posted Sep 29, 2014

Participant flow

Participant flow — Overall Study
MilestoneTrastuzumab
Started2
Completed0
Not completed2
Withdrew: Study terminated by sponsor2

Outcome measures

PrimaryQuality of Life Score

Participants rated their quality of life on a visual analog scale (VAS) at the end of each cycle for Cycles 7-14. The left-end of the VAS represented the lowest-rated quality of life and the right-end of the VAS represented the highest-rated quality of life. Both the mean ratings for injections into the thigh and the upper arm and the minimum ratings for during injections into the thigh and the upper arm are reported. Quality of life scores ranged from 1 to 100 with a higher score indicating a better rated quality of life.

Time frame:
Cycles 7-14 (Weeks 19-42, 24 weeks total)

No measurements were reported for this outcome.

SecondaryOverall Survival

Overall survival was defined as the time in months from Baseline to death from any cause.

Time frame:
Baseline to the end of the study (up to 54 weeks)

No measurements were reported for this outcome.

SecondaryDisease-free Survival

Disease-free survival was defined as the time in months from Baseline to disease recurrence or death, whichever occurred first.

Time frame:
Baseline to the end of the study (up to 54 weeks)

No measurements were reported for this outcome.

SecondaryHealth Care Provider's Satisfaction With the Injection Site

The health care provider for each participant was asked to rate their satisfaction with the 2 injection sites, thigh and upper arm, on a scale of 1 to 10, where 10 represents greater satisfaction. Ratings were made at the end of Cycles 10 and 14.

Time frame:
End of Cycles 10 and 14 (Weeks 30 and 42)

No measurements were reported for this outcome.

SecondaryParticipant's Satisfaction With the Injection Site

Each participant was asked to rate their satisfaction with the 2 injection sites, thigh and upper arm, on a scale of 1 to 10, where 10 represents greater satisfaction. Ratings were made at the end of Cycles 10 and 14.

Time frame:
End of Cycles 10 and 14 (Weeks 30 and 42)

No measurements were reported for this outcome.

SecondaryPercentage of Participants Preferring Each Injection Site

Participants were asked which of the 2 injection sites was their preferred site at the end of Cycle 14.

Time frame:
End of Cycle 14 (Week 42)

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Trastuzumab—0/2 (0%)1/2 (50%)
Most frequent other events
Most frequent other events
EventTrastuzumab
Common coldRespiratory, thoracic and mediastinal disorders1/2

Baseline characteristics

Full analysis set: All participants who were enrolled in the study.

Age, Continuous
Age, Continuous(years)Trastuzumab
Mean38.0 ± 14.1
Sex: Female, Male
Sex: Female, Male(Participants)Trastuzumab
Female2
Male0
08

Study locations

2 sites
  • Innsbruck, 6020, Austria
  • Salzburg, 5020, Austria
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2013, a primary completion of Oct 2013 and a completion of Oct 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2014, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2013
First posted
Aug 27, 2013
Start
Sep 2013
Primary completionActual
Oct 2013
CompletionActual
Oct 2013
Results first posted
Sep 29, 2014
Last update
Sep 29, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 29, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01928615
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Aug 27, 2013
Start date
Sep 2013
Primary completion
Oct 2013
Completion
Oct 2013
Results posted
Sep 29, 2014
Last update
Sep 29, 2014

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab

Start the discussion